THE neurologic manifestations of Central-nervous-system involvement in acute leukemia have been very well described. 1–7 Although involvement of the brain is not rare 7,8 greater emphasis has been ...
In a recent study published in Nanomedicine: Nanotechnology, Biology and Medicine, researchers evaluated the biodistribution of cannabidiol (CBD) emulsion and nanoparticles in the central nervous ...
A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection ...
Study design: Case series of a consecutive sample. Retrospective audit. Objective: To analyze the long-term safety and efficacy of intrathecal baclofen (ITB), and technical incidents. Setting: ...
Gene delivery into the spinal cord provides a potential approach to the treatment of spinal cord traumatic injury, amyotrophic lateral sclerosis, and spinal muscular atrophy. These disorders progress ...
September 14, 2012 — The US Food and Drug Administration (FDA) has approved a new catheter (Ascenda, Medtronic Inc) for use in the delivery of intrathecal baclofen (ITB) therapy. According to the ...
Panelists discuss how intrathecal delivery of onasemnogene abeparvovec in the STEER study demonstrates statistically significant motor function improvements in older patients with SMA (ages 2-18 years ...
Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03) No significant financial relationships to disclose ...
The following represents disclosure information provided by author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
January 29, 2009 (Honolulu, Hawaii) — Intrathecal therapies can relieve pain and improve long-term function, report specialists, but there are risks that should be taken into consideration. Speakers ...
Credit: FDA. The FDA has received reports of tranexamic acid injection being erroneously administered intrathecally in the perioperative setting instead of the intended intrathecal anesthetic (eg, ...
Novartis has reported phase 1/2 trial results with its intrathecal formulation of gene therapy Zolgensma, placed under a clinical hold by the FDA last year, backing up its safety and efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results